前列腺癌孤立性局部复发再放疗:64例挽救性立体定向体部放疗的单中心系列
回顾性纳入64例根治性或挽救性外照射或近距离治疗后生化失败且影像证实孤立性局部复发的前列腺癌患者,接受挽救性立体定向体部放疗(再外照射)。中位随访26.1个月,2年局部控制率75%、生化无复发生存率40%、临床无复发生存率53%;BED≥130 Gy时1年生化及临床无进展生存率分别为85%和90%。作者认为该治疗安全、可行、无创,但需进一步研究确定最佳患者选择、剂量和体积参数。
要点
- 孤立性局部复发前列腺癌行挽救性SBRT再照射,中位总剂量30 Gy/5次(BED 150 Gy)。
- 2年局部控制率75%、生化无复发生存率40%、临床无复发生存率53%。
- BED≥130 Gy时1年生化及临床无进展生存率分别为85%和90%。
核心结论
- 挽救性SBRT(再外照射)治疗前列腺癌孤立性局部复发安全、可行且无创;给予BED≥130 Gy时肿瘤控制满意且毒性极低;需进一步研究确定最佳患者选择、剂量和体积参数。
研究设计与样本
- 单中心回顾性研究,纳入64例根治性或挽救性外照射或近距离治疗后生化失败且证据显示孤立性局部复发的前列腺癌患者,接受挽救性SBRT(再外照射),采用影像引导放疗(RapidArc®、VERO®和CyberKnife®)。
诊断标准与关键数值
- 中位总剂量30 Gy分5次,BED 150 Gy;BED≥130 Gy时1年生化及临床无进展生存率分别为85%和90%;2年局部控制率75%、生化无复发生存率40%、临床无复发生存率53%。
临床应用与阅片要点
- 对于根治性或挽救性外照射或近距离治疗后生化失败且影像(胆碱-PET或MRI)及PSA演变等诊断要素一致提示孤立性局部复发的前列腺癌患者,可考虑行挽救性SBRT再照射;给予BED≥130 Gy时可能获得较好肿瘤控制。
局限性
- 原文报告需进一步研究以确定最佳患者选择、剂量和体积参数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE:: To evaluate high-precision external beam reirradiation (re-EBRT) for local relapse of prostate cancer (PCa) after radiotherapy.
METHODS:: This retrospective study included patients with biochemical failure and evidence of isolated local recurrence of PCa after radical/salvage EBRT or brachytherapy that received salvage stereotactic body radiation therapy (SBRT, re-EBRT). Biopsy was not mandatory if all diagnostic elements were univocal (prostate specific antigen evolution, choline-positron emission tomography or magnetic resonance imaging). Salvage SBRT (re-EBRT) was delivered with image-guided radiation therapy (RapidArc®, VERO® and CyberKnife®).
RESULTS:: Data of 64 patients were included, median age at salvage SBRT was 73.2 years, median pre-salvage SBRT prostate specific antigen was 3.89 ng ml-1 . Median total dose was 30 Gy in five fractions, biologically effective dose (BED) of 150 Gy. One acute G3 genitourinary event and one late G3 genitourinary event were observed. No G ≥ 3 bowel toxicity was registered. At the median follow-up of 26.1 months, tumor progression was observed in 41 patients (64%). 18 patients (28%) experienced local relapse. 2-year local control, biochemical and clinical relapse free survival rates were 75, 40 and 53%, respectively. With BED ≥130 Gy 1-year biochemical and clinical progression-free survival rate were 85 and 90%, respectively.
CONCLUSIONS:: Salvage SBRT (re-EBRT) for isolated local PCa recurrence is a safe, feasible and noninvasive salvage treatment. Further investigation is warranted to define the optimal patient selection, dose and volume parameters.
ADVANCES IN KNOWLEDGE:: Salvage SBRT reirradiation for the locally recurrent PCa offer a satisfactory tumor control and excellent toxicity profile, if BED ≥130 Gy is administered.
引用
- Jereczek-Fossa BA, Rojas DP, Zerini D, et al. Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT). Br J Radiol. 2018. PMID: 30379566. doi:10.1259/bjr.20180494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。